查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1968401

滤泡性甲状腺癌治疗市场－全球产业规模、份额、趋势、机会、预测：按类型、最终用户、地区和竞争对手划分，2021-2031年

Follicular Thyroid Cancer Drug Sales Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球滤泡性甲状腺癌治疗市场预计将从 2025 年的 7.6 亿美元成长到 2031 年的 10.7 亿美元，复合年增长率为 5.81%。

这个市场领域主要包括针对转移性或不可切除甲状腺癌患者的标靶治疗，例如蛋白酪氨酸激酶抑制剂和放射性碘疗法。甲状腺恶性肿瘤发生率的不断上升以及识别需要特定药物治疗的基因突变的精准度不断提高，是推动该行业成长的根本原因。根据美国癌症协会 (ACS) 的数据，预计到 2025 年，美国将新增 44,020 例甲状腺癌病例，这一数字凸显了对有效肿瘤治疗方案的持续强劲的需求。

市场概览
预测期 2027-2031
市场规模：2025年 7.6亿美元
市场规模：2031年 10.7亿美元
复合年增长率：2026-2031年 5.81%
成长最快的细分市场 乳头状癌
最大的市场 北美洲

儘管成长要素强劲，但由于长期全身性治疗带来的严重毒性，市场仍面临许多挑战。这些不良反应常常迫使医疗专业人员减少剂量或完全停止治疗，对患者的治疗顺从性和临床疗效产生负面影响。加上长期治疗方法带来的沉重经济负担，这些安全问题构成了重大障碍，可能阻碍全球滤泡性甲状腺癌治疗市场的发展和收入潜力。

市场驱动因素

推动市场收入成长的关键因素是创新标靶治疗（尤其是针对放射性碘抗药性滤泡性甲状腺癌的疗法）的监管核准加速。临床通讯协定正在迅速发展，从对晚期疾病疗效有限的传统特异性疗法转向针对特定路径（例如VEGFR和RET）的蛋白酪氨酸激酶抑制剂（TKI）。领先的製药研发公司强劲的财务业绩表明，这种向高价值精准医疗的转变显而易见。例如，Exelixis公司在2024年11月公布的第三季Cabozantinib系列药物净销售额为4.781亿美元，这充分体现了这些特异性治疗方法的庞大市场价值。随着监管机构不断核准在无恶化生存期方面疗效确切的药物，市场单价和使用率持续上涨。

同时，全球甲状腺恶性肿瘤发生率的上升扩大了目标患者群体，也使得诊断和治疗资源的需求日益增长。这种疾病盛行率上升的趋势在全球范围内普遍存在，导致各个医疗保健系统对有效的管理策略的需求持续增加。加拿大癌症协会发布的《2024年加拿大癌症统计》报告估计，当年将有6,600名加拿大人被诊断出患有甲状腺癌，凸显了已开发国家日益沉重的负担。患者数量的增加，加上基因组分析技术的进步，提高了标靶疗法的商业性可行性。礼来公司宣布，其Letevmo产品2023年全年全球销售额达到2.536亿美元，证实了目标患者群体的扩大正在推动标靶治疗领域的显着销售成长。

市场挑战

长期全身性治疗带来的严重毒性持续限制着全球滤泡性甲状腺癌治疗市场的发展。强效药物常引起不利事件，降低病人遵从性，迫使临床医师中断或永久停止治疗方案。治疗中断显着缩短了平均治疗持续时间，进而限制了每位患者的累积销售额以及这些疗法产生的总收入。

此外，不利事件的高发生率阻碍了相当一部分患者坚持用药，使市场无法充分利用疾病的高发生率。鑑于需要长期治疗的患者数量庞大，而他们正是该领域的核心基本客群，因此这个问题至关重要。根据美国癌症协会统计，到2025年，美国将有约859,890名女性甲状腺癌倖存者，这意味着大量患者面临因药物毒性而中断治疗的风险。因此，由于安全问题导致长期药物治疗难以持续，直接阻碍了市场的整体成长。

市场趋势

目前的治疗格局正因联合治疗通讯协定研究的拓展而重塑。这源自于临床医师为克服进行性恶性肿瘤单药治疗的限製而做出的努力。研究人员正积极评估蛋白酪氨酸激酶抑制剂与其他药物合併使用的方案，以期产生协同效应，延长对标准治疗产生抗药性的患者的无恶化生存期。LENVIMA等成熟药物的商业性永续性体现了这种向多方面治疗框架的策略转变。Eisai在2025年5月发布的「2024财年合併会计业绩」中报告称，LENVIMA的全球销售额达到3285亿日元，这印证了该类治疗层级在日益复杂且不断扩展的治疗格局中持续的高价值。

同时，免疫疗法和免疫查核点抑制剂方案的出现，对于放射性碘抗药性疾病患者而言是一项重大进展。这些生物製药针对PD-1等通路，为肿瘤突变负荷高和微卫星不稳定性高的病例提供了新的作用机制，在激酶抑制剂无效或耐受性差时，提供了一种挽救性治疗选择。这一治疗方法浪潮的大规模影响正在改变全球肿瘤领域的筹资策略，促使人们更加关注甲状腺区域合格适应症中查核点抑制剂的可靠供应。根据默克公司2025年10月发布的第三季财报，Keytruda的全球销售额达到81亿美元，这反映了免疫肿瘤药物在重新定义固体癌治疗标准方面的主导作用。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：滤泡性甲状腺癌治疗药物的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依类型（乳头状癌、滤泡状癌、其他）
    • 依最终使用者（医院/诊所、门诊中心、其他）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美滤泡性甲状腺癌治疗药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲滤泡性甲状腺癌治疗药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区滤泡性甲状腺癌治疗药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲滤泡性甲状腺癌治疗药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲滤泡性甲状腺癌治疗药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章 全球滤泡性甲状腺癌治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • GlaxoSmithKline Plc
  • Novartis AG
  • Merck & Co
  • Pfizer Inc
  • Exelixis Inc
  • Celgene Corporation
  • Bayer AG
  • Eisai Co., Ltd
  • Teva Pharmaceuticals Industries Ltd.
  • AstraZeneca Pharmaceuticals LP

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 23875

The Global Follicular Thyroid Cancer Drug Sales Market is projected to expand from USD 0.76 Billion in 2025 to USD 1.07 Billion by 2031, registering a CAGR of 5.81%. This market sector primarily consists of targeted therapies, such as tyrosine kinase inhibitors, alongside radioactive iodine treatments intended for patients with metastatic or unresectable conditions. The growth of this industry is fundamentally supported by the increasing prevalence of thyroid malignancies and the improved identification of genetic mutations that require specific pharmacological responses. Data from the American Cancer Society indicates that there were an estimated 44,020 new thyroid cancer diagnoses in the United States in 2025, a figure that highlights the substantial and steady demand for effective oncological solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 0.76 Billion
Market Size 2031USD 1.07 Billion
CAGR 2026-20315.81%
Fastest Growing SegmentPapillary Carcinoma
Largest MarketNorth America

Despite these robust growth drivers, the market encounters significant obstacles due to the severe toxicity profiles linked to long-term systemic therapies. These adverse effects frequently force medical practitioners to lower dosages or discontinue treatment altogether, which negatively affects patient adherence and clinical outcomes. When combined with the considerable economic strain of maintaining prolonged therapeutic regimens, these safety issues create a notable barrier that could hinder the broader development and revenue potential of the Global Follicular Thyroid Cancer Drug Sales Market.

Market Driver

A primary catalyst for revenue growth within the market is the accelerated regulatory approval of innovative targeted therapies, specifically for radioiodine-refractory follicular thyroid cancer. Clinical protocols are rapidly evolving to favor tyrosine kinase inhibitors (TKIs) that target distinct pathways like VEGFR and RET, replacing older, nonspecific treatments that provided limited efficacy in advanced disease stages. This transition toward high-value precision medicine is evidenced by the robust financial results of major pharmaceutical developers; for instance, Exelixis, Inc. reported in November 2024 that its cabozantinib franchise achieved net product revenues of $478.1 million during the third quarter, demonstrating the significant market value of these specialized interventions. As regulatory agencies continue to approve agents with proven benefits in progression-free survival, the market is experiencing a sustained rise in both unit price and utilization.

Simultaneously, the increasing global incidence of thyroid malignancies is enlarging the addressable patient population, necessitating a higher volume of diagnostic and therapeutic resources. This rising trend in disease prevalence is observed internationally, generating consistent demand for effective management strategies across various healthcare systems. The Canadian Cancer Society's 'Canadian Cancer Statistics 2024' report estimated that 6,600 Canadians would be diagnosed with thyroid cancer that year, underscoring the growing burden in developed nations. This expanding patient volume, coupled with advancements in genomic profiling, reinforces the commercial viability of niche drugs; Eli Lilly and Company noted that worldwide revenue for Retevmo grew to $253.6 million for the full year 2023, confirming how the growing pool of eligible patients drives substantial sales in the targeted therapy segment.

Market Challenge

The expansion of the Global Follicular Thyroid Cancer Drug Sales Market is continually impeded by the severe toxicity profiles associated with long-term systemic therapy. Potent pharmacological agents frequently trigger adverse events that undermine patient compliance, compelling clinicians to interrupt dosing schedules or permanently cease administration. This disruption in the treatment continuum significantly shortens the average duration of therapy, which in turn reduces the cumulative volume of drug units sold per patient and limits the total revenue generated from these therapeutics.

Furthermore, the market struggles to fully capitalize on disease prevalence because the high incidence of adverse events prevents a significant portion of the patient population from maintaining consistent adherence. This issue is critical given the large volume of patients requiring extended management who constitute the core customer base. According to the American Cancer Society, there were approximately 859,890 female thyroid cancer survivors in the United States in 2025, a statistic that illustrates the vast scale of the patient pool susceptible to toxicity-related discontinuation. Consequently, the difficulty in sustaining long-term pharmacologic regimens due to safety concerns directly hampers the market's overall growth trajectory.

Market Trends

The treatment landscape is currently being reshaped by the rising investigation of combination therapy protocols, as clinicians aim to surpass the limitations of monotherapy for aggressive malignancies. Researchers are actively evaluating regimens that pair tyrosine kinase inhibitors with other agents to produce synergistic effects and extend progression-free survival in patients who have developed resistance to standard care. This strategic pivot toward multi-modal frameworks is exemplified by the commercial resilience of established agents like Lenvima; Eisai Co., Ltd. reported in its 'Consolidated Financial Report for Fiscal 2024' in May 2025 that global revenue for Lenvima reached ¥328.5 billion, underscoring the sustained high value of this therapeutic class as it expands into complex treatment settings.

In parallel, the emergence of immunotherapy and immune checkpoint inhibitor regimens signifies a critical evolution for patients with radioiodine-refractory disease. By targeting pathways such as PD-1, these biologics offer a novel mechanism of action for cases exhibiting high tumor mutational burden or microsatellite instability, providing a salvage option when kinase inhibitors are ineffective or poorly tolerated. The massive scale of this therapeutic wave is influencing oncology procurement strategies globally, ensuring that checkpoint inhibitors are accessible for eligible niche indications within the thyroid segment. As reported by Merck & Co., Inc. in October 2025 regarding their third-quarter financial results, Keytruda generated worldwide sales of $8.1 billion, a figure that reflects the dominant role of immuno-oncology agents in redefining standards of care across solid tumors.

Key Market Players

  • GlaxoSmithKline Plc
  • Novartis AG
  • Merck & Co
  • Pfizer Inc
  • Exelixis Inc
  • Celgene Corporation
  • Bayer AG
  • Eisai Co., Ltd
  • Teva Pharmaceuticals Industries Ltd.
  • AstraZeneca Pharmaceuticals LP

Report Scope

In this report, the Global Follicular Thyroid Cancer Drug Sales Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Follicular Thyroid Cancer Drug Sales Market, By Type

  • Papillary Carcinoma
  • Follicular Carcinoma
  • Others

Follicular Thyroid Cancer Drug Sales Market, By End User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Follicular Thyroid Cancer Drug Sales Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Follicular Thyroid Cancer Drug Sales Market.

Available Customizations:

Global Follicular Thyroid Cancer Drug Sales Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Follicular Thyroid Cancer Drug Sales Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Papillary Carcinoma, Follicular Carcinoma, Others)
    • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Follicular Thyroid Cancer Drug Sales Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Follicular Thyroid Cancer Drug Sales Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Follicular Thyroid Cancer Drug Sales Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Follicular Thyroid Cancer Drug Sales Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End User

7. Europe Follicular Thyroid Cancer Drug Sales Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Follicular Thyroid Cancer Drug Sales Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Follicular Thyroid Cancer Drug Sales Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Follicular Thyroid Cancer Drug Sales Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Follicular Thyroid Cancer Drug Sales Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Follicular Thyroid Cancer Drug Sales Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Follicular Thyroid Cancer Drug Sales Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Follicular Thyroid Cancer Drug Sales Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Follicular Thyroid Cancer Drug Sales Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Follicular Thyroid Cancer Drug Sales Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Follicular Thyroid Cancer Drug Sales Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Follicular Thyroid Cancer Drug Sales Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Follicular Thyroid Cancer Drug Sales Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Follicular Thyroid Cancer Drug Sales Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Follicular Thyroid Cancer Drug Sales Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Follicular Thyroid Cancer Drug Sales Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End User

10. South America Follicular Thyroid Cancer Drug Sales Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Follicular Thyroid Cancer Drug Sales Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Follicular Thyroid Cancer Drug Sales Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Follicular Thyroid Cancer Drug Sales Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Follicular Thyroid Cancer Drug Sales Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GlaxoSmithKline Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Merck & Co
  • 15.4. Pfizer Inc
  • 15.5. Exelixis Inc
  • 15.6. Celgene Corporation
  • 15.7. Bayer AG
  • 15.8. Eisai Co., Ltd
  • 15.9. Teva Pharmaceuticals Industries Ltd.
  • 15.10. AstraZeneca Pharmaceuticals LP

16. Strategic Recommendations

17. About Us & Disclaimer